`
`APPROVAL PACKAGE FOR:
`
`APPLICATION NUMBER
`
`21-372
`
`Microbiology Review(s)
`
`
`
`Product Quality Microbiology Review
`Review for HFD-180
`
`May 12, 2003
`
`NDA: 21-372
`
`Drug Product Name
`Proprietary:
`Non-proprietary: Palonosetron Hydrochloride Injection
`Drug Product Classification: anti emetic
`
`Review Number: 1
`
`Subject of this Review
`Submission Date: September 26, 2002
`Receipt Date:
`Consult Date: October 25, 2003
`
`Date Assigned for Review: November 7, 2002
`
`Submission History (for amendments only):
`
`.
`Applicant/Sponsor
`Name:
`Helsinn Healthcare SA
`
`Address:
`
`Via Plan Scairolo
`
`6912 Pazzallo (Lugano) - Switzerland
`Representative:
`_
`Telephone:
`Authorized Agent: Dr. Craig Lehmann
`'
`August Consulting Inc.
`515 Capitol of Texas Highway, Suite 150
`Austin, TX 78746
`-
`
`(512) 347-1755
`
`Name of Reviewer:
`
`James L. McVey
`
`Conclusion: This application is recommended for approval from a product
`quality microbiology perspective.
`
`
`
`NDA 21—372
`
`Microbiology Review #1
`
`Product Quality Microbiology Data Sheet
`
`A.
`
`l.
`
`2.
`
`3.
`
`_ TYPE OF SUPPLEMENT:
`
`SUPPLEMENT PROVIDES FOR:
`
`MANUFACTURING SITE: The drug product will be manufactured,
`tested for release and for stability and released for commercial use by:
`
`\
`
`Vs
`
`Additional testing site:
`
`.—
`
`_
`-
`Additional ..
`Helsinn Birex Pharmaceuticals Ltd.
`Damastown
`Mulhuddart — Dublin 15
`Ireland
`
`‘ site:
`
`4.
`
`5.
`
`6.
`
`DOSAGE FORM, ROUTE OF ADMINISTRATION AND
`STRENGTH/POTENCY: 0.25 mg/ 5 mL vial for intravenous
`administration.
`
`METHOD(S) OF STERILIZATION: The product is
`followed by '-
`\—-
`fisterilization"
`
`——'——
`
`PHARMACOLOGICAL CATEGORY: anti emetic
`
`B.
`
`INC/RELATED DOCUMENTS:
`SUPP,
`DMF [16063 for drug substance — not reviewed for product quality microbiology.
`
`C.
`
`REMARKS: Well organized and assembled application.
`
`filename: 21372rl
`
`/—.\
`
`Page 2 of8
`
`
`
`NDA 21-372
`
`Microbiology Review #1
`
`Executive Summary
`
`1.
`
`Recommendations
`
`- A.
`
`Recommendation on Approvability — This application is
`recommended for approval from a product quality microbiology
`perspective.
`
`B.
`
`Recommendations on Phase 4 Commitments and/or
`
`Agreements, if Approvable -
`
`II.
`
`Summary of Microbiology Assessments
`
`A.
`
`Brief Description of the Manufacturing Processes that relate to
`Product Quality Microbiology — The product is \_ sterilized
`—
`to _
`
`
`v _ sterilized with a validated
`
`~j
`
`fi\
`
`B.
`
`C.
`
`Brief Description of Microbiology Deficiencies — None.
`
`Assessment of Risk Due to Microbiology Deficiencies — Minimal
`risk is seen from a product quality microbiology perspective.
`
`lIl.
`
`Administrative
`
`A.
`
`B.
`
`C.
`
`Reviewer's Signature
`
`Endorsement Block
`
`Review Microbiologist. J.L. McVey
`Microbiology Supervisor. PH. Cooney
`
`CC Block
`cc:
`
`DFS
`
`HFD- 805/McVey/21372r1
`
`Page 3 of 8
`
`
`
`
`
` : RedéCted f7_.
`
`pages of trade
`
`
`
`--------------------------*n-c-Dou-uboun-I-I---------------a-------n-n-I-n-n-I-n-n-n-n-I-uh-----------------------u
`
`This'Is a representation of an electronic record that was signed electronically and
`this page is the manifestation of the electronic signature.
`
`/8/
`
`James McVey'
`5/28/03 11:10:31 AM
`MICROBIOLOGIST
`
`Peter Cooney
`5/29/03 09:05:23 AM
`MICROBIOLOGIST
`
`